Combination talabostat and pembrolizumab has shown antitumor activity in patients who have metastatic castration-resistant prostate cancer with small-cell neuroendocrine carcinoma phenotype.
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Treatment with radiolabeled J591 plus ketoconazole and hydrocortisone may delay time to metastasis in patients with high-risk nmCRPC.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
A longer course of androgen deprivation therapy does not improve outcomes in patients with localized, high-risk prostate cancer receiving I-125 brachytherapy and external beam radiotherapy, a phase 3 trial suggests.
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.
Adding niraparib to AAP improves rPFS in patients with BRCA-mutated metastatic castration-resistant prostate cancer, a phase 3 trial suggests.
